Skip to content
OpenCapital
Get started

ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q2 2025 earnings

Reported August 12, 2025 · Before market open

Diluted EPS-$1.25Miss by $0.23
Revenue estimate$3.8M
EPS estimate-$1.02

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$15.0M
EPS estimate-$0.89

Versus estimates

Revenue

Q1 2025$10.0MBeat by $8.8MQ4 2024$5.0M

Diluted EPS

Q1 2026-$1.46Beat by $0.01Q4 2025-$1.10Miss by $0.10Q3 2025-$1.22Miss by $0.35
Q2 2025-$1.25Miss by $0.23
Q1 2025-$0.80Beat by $0.31Q4 2024-$3.99Miss by $3.07

Ask the moment ProShares UltraPro Short NASDAQ Biotechnology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ProShares UltraPro Short NASDAQ Biotechnology report Q2 2025 earnings?
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q2 2025 earnings on August 12, 2025 before market open.
What were ProShares UltraPro Short NASDAQ Biotechnology's Q2 2025 revenue and EPS?
ProShares UltraPro Short NASDAQ Biotechnology reported diluted EPS of $-1.25 for Q2 2025.
Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q2 2025?
EPS missed the consensus estimate of $-1.02 by $0.23.
How did ProShares UltraPro Short NASDAQ Biotechnology's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 26.1% from $-0.99.
Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-011147) directly on SEC EDGAR. The filing index links above go to sec.gov.